Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume 23, Issue 10, Pages 1762-1773
Publisher
Oxford University Press (OUP)
Online
2017-08-24
DOI
10.1097/mib.0000000000001212
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease
- (2017) Jeffrey S. Hyams et al. GASTROENTEROLOGY
- Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn’s Disease
- (2015) Victoria Grossi et al. Clinical Gastroenterology and Hepatology
- An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
- (2015) David J. Gibson et al. Clinical Gastroenterology and Hepatology
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics
- (2015) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Significance of low level infliximab in the absence of anti-infliximab antibodies
- (2015) Bella Ungar WORLD JOURNAL OF GASTROENTEROLOGY
- Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
- (2014) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease
- (2014) Elaheh Vahabnezhad et al. INFLAMMATORY BOWEL DISEASES
- Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohnʼs Disease
- (2014) Peter C. Church et al. INFLAMMATORY BOWEL DISEASES
- Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial
- (2013) Jacques Cosnes et al. GASTROENTEROLOGY
- Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
- (2013) Julián Panés et al. GASTROENTEROLOGY
- Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort Study
- (2013) Nabeel Khan et al. GASTROENTEROLOGY
- Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease
- (2013) Thomas D. Walters et al. GASTROENTEROLOGY
- Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease
- (2013) Sorcha O’Meara et al. INFLAMMATORY BOWEL DISEASES
- High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
- (2013) Fernando Magro et al. Journal of Crohns & Colitis
- Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
- (2012) C. Reenaers et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-infliximab antibodies in inflammatory bowel disease
- (2012) Lennard Y.W. Lee et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
- (2012) Millie D. Long et al. GASTROENTEROLOGY
- Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease
- (2012) Shane M. Devlin et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
- (2012) Amit Assa et al. Journal of Crohns & Colitis
- Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
- (2011) C. Steenholdt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
- (2011) Matthias Jürgens et al. Clinical Gastroenterology and Hepatology
- Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension
- (2011) Jeffrey Hyams et al. CURRENT MEDICAL RESEARCH AND OPINION
- Meta-analysis
- (2011) Ziwei Lin et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
- (2011) Laurent Peyrin–Biroulet et al. GASTROENTEROLOGY
- Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response
- (2011) María Chaparro et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?
- (2010) Geert R D'Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
- (2010) Jeffrey S Hyams et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
- (2010) H. Sokol et al. GUT
- Pediatric modification of the Montreal classification for inflammatory bowel disease
- (2010) Arie Levine et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab
- (2009) Alan C. Moss et al. DIGESTIVE DISEASES AND SCIENCES
- Durability of infliximab in Crohnʼs disease
- (2009) Jason E. Gonzaga et al. INFLAMMATORY BOWEL DISEASES
- Growth Abnormalities Persist in Newly Diagnosed Children With Crohn Disease Despite Current Treatment Paradigms
- (2009) Marian Pfefferkorn et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Combination Therapy With Infliximab and Immunomodulators: Is the Glass Half Empty?
- (2008) Amar R. Deshpande et al. GASTROENTEROLOGY
- Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease
- (2008) Jeffrey S. Hyams et al. INFLAMMATORY BOWEL DISEASES
- Efficacy of Infliximab in Pediatric Crohnʼs Disease: A Randomized Multicenter Open-Label Trial Comparing Scheduled to On Demand Maintenance Therapy
- (2008) Frank M. Ruemmele et al. INFLAMMATORY BOWEL DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now